Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
During the annual event, volunteers advocated for the PASTEUR Act and the HELP Copays Act, two bipartisan pieces of legislation that could have substantial, positive impact on the CF community.
|
3 min read
More than 60 teens from across the country — 25 of whom live with cystic fibrosis — participated online and on Capitol Hill in the Foundation’s Teen Advocacy Day to advocate for the CF community.
|
4 min read
More than 160 people with CF and their loved ones from across the country advocated for a more robust antibiotics pipeline during the CF Foundation's virtual March on the Hill.
|
3 min read
Nearly 200 teens from across the country -- nearly half living with cystic fibrosis -- participated in the Foundation's Virtual Teen Advocacy Day to advocate for the CF community.
|
3 min read
More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.
|
3 min read
On Monday, April 1, the CF Foundation joined 16 other patient and consumer groups in filing an amicus brief supporting vital patient protections and coverage expansion included in the Affordable Care Act in the appeal of the Texas v. United States decision, which struck down the constitutionality of the health care law in 2018.
|
4 min read
Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
|
2 min read
The Cystic Fibrosis Foundation responds to the Institute for Clinical and Economic Review's assessment of the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
|
4 min read
The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.
|
2 min read